About Ral guanine nucleotide dissociation stimulator-like 3
Ral guanine nucleotide dissociation stimulator-like 3 (RGL3) is a protein
from Homo sapiens identified by UniProt accession
Q3MIN7, 710 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Ral guanine nucleotide dissociation stimulator-like 3 |
|---|
| UniProt accession | Q3MIN7 |
|---|
| Gene | RGL3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 710 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q3MIN7-F1 | alphafold | PREDICTED | 72.01 | — |
Amino-acid sequence (710 residues)
MERTAGKELA LAPLQDWGEE TEDGAVYSVS LRRQRSQRRS PAEGPGGSQA PSPIANTFLH YRTSKVRVLR AARLERLVGE LVFGDREQDP SFMPAFLATY RTFVPTACLL GFLLPPMPPP PPPGVEIKKT AVQDLSFNKN LRAVVSVLGS WLQDHPQDFR DHPAHSDLGS VRTFLGWAAP GSAEAQKAEK LLEDFLEEAE REQEEEPPQV WTGPPRVAQT SDPDSSEACA EEEEGLMPQG PQLLDFSVDE VAEQLTLIDL ELFSKVRLYE CLGSVWSQRD RPGAAGASPT VRATVAQFNT VTGCVLGSVL GAPGLAAPQR AQRLEKWIRI AQRCRELRNF SSLRAILSAL QSNPIYRLKR SWGAVSREPL STFRKLSQIF SDENNHLSSR EILFQEEATE GSQEEDNTPG SLPSKPPPGP VPYLGTFLTD LVMLDTALPD MLEGDLINFE KRRKEWEILA RIQQLQRRCQ SYTLSPHPPI LAALHAQNQL TEEQSYRLSR VIEPPAASCP SSPRIRRRIS LTKRLSAKLA REKSSSPSGS PGDPSSPTSS VSPGSPPSSP RSRDAPAGSP PASPGPQGPS TKLPLSLDLP SPRPFALPLG SPRIPLPAQQ SSEARVIRVS IDNDHGNLYR SILLTSQDKA PSVVRRALQK HNVPQPWACD YQLFQVLPGD RVLLIPDNAN VFYAMSPVAP RDFMLRRKEG TRNTLSVSPS
Explore Ral guanine nucleotide dissociation stimulator-like 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets